WA
NBIX icon

WPG Advisers’s Neurocrine Biosciences NBIX Stock Holding History

WPG Advisers’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.2K Hold
102
– – 0.01% 591
2026
Q1 		$13.4K Sell
102
-80
-44% -$10.6K 0.01% 586
2025
Q4 		$25.8K Sell
182
-40
-18% -$5.79K 0.02% 445
2025
Q3 		$31.2K Buy
222
+40
+22% +$5.42K 0.02% 404
2025
Q2 		$22.9K Sell
182
-111
-38% -$12.7K 0.02% 463
2025
Q1 		$32.4K Sell
293
-194
-40% -$24.6K 0.03% 367
2024
Q4 		$66.5K Buy
+487
New +$60.2K 0.06% 236

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

WPG Advisers's NBIX Position: Q2 2026 in Review

WPG Advisers held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 102 shares worth $17.2K. The position accounts for 0.01% of the portfolio, ranked #591.

WPG Advisers first reported a position in NBIX in Q4 2024 and has held it in 7 quarters since. The position peaked at $66.5K in Q4 2024. 388 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • WPG Advisers held 102 shares of Neurocrine Biosciences worth $17.2K as of Q2 2026.
  • WPG Advisers left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up 0.01% of WPG Advisers's portfolio in Q2 2026, its #591 holding.
  • WPG Advisers first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 7 quarters since.
  • WPG Advisers's Neurocrine Biosciences position peaked at $66.5K in Q4 2024.
  • 388 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on WPG Advisers's 13F filing for Q2 2026, filed 6 Aug 2026.